The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease. uri icon

authors

  • Karuppagounder, Senthilkumar S
  • Brahmachari, Saurav
  • Lee, Yunjong
  • Dawson, Valina L
  • Ted M. Dawson, MD, PhD
  • Ko, Han Seok

publication date

  • January 1, 2014